Trefoil Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series A2

  • Latest Deal Amount
  • $4.56M

  • Investors
  • 12

Trefoil Therapeutics General Information

Description

Developer of corneal therapeutics designed to facilitate the treatment of ophthalmic diseases. The company's therapy is focused on leveraging its engineered fibroblast growth factor-one protein technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases and help regenerate the endothelial cell layer and eliminate the symptoms associated with this condition that leads to the loss of vision, enabling ophthalmologists to treat patients with severe corneal endothelial diseases and epithelial disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 6330 Nancy Ridge Drive
  • Suite 103
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 6330 Nancy Ridge Drive
  • Suite 103
  • San Diego, CA 92121
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Trefoil Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series A2) 06-May-2025 $4.56M Completed Clinical Trials - Phase 2
5. Later Stage VC (Series A1) 22-Mar-2022 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series A) 05-Aug-2019 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series 1) 05-Jan-2017 Completed Startup
2. Grant 20-Oct-2015 Completed Startup
1. Accelerator/Incubator 01-Jan-2013 Completed Startup
To view Trefoil Therapeutics’s complete valuation and funding history, request access »

Trefoil Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-2
To view Trefoil Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Trefoil Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of corneal therapeutics designed to facilitate the treatment of ophthalmic diseases. The company's therapy is
Drug Discovery
San Diego, CA
10 As of 2026

Cambridge, MA
 

Allschwil, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Trefoil Therapeutics Competitors (92)

One of Trefoil Therapeutics’s 92 competitors is Casma Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Casma Therapeutics Venture Capital-Backed Cambridge, MA
Alentis Therapeutics Venture Capital-Backed Allschwil, Switzerland
Cognition Therapeutics Formerly VC-backed New York, NY
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Immusoft Venture Capital-Backed Seattle, WA
You’re viewing 5 of 92 competitors. Get the full list »

Trefoil Therapeutics Patents

Trefoil Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024247068-A1 Recombinant modified fibroblast growth factors and therapeutic uses thereof Pending 28-Mar-2023
EP-4687945-A2 Recombinant modified fibroblast growth factors and therapeutic uses thereof Pending 28-Mar-2023
US-20260265323-A1 Recombinant modified fibroblast growth factors and therapeutic uses thereof Pending 28-Mar-2023
WO-2024206358-A2 Recombinant modified fibroblast growth factors and therapeutic uses thereof Inactive 28-Mar-2023
WO-2024206358-A3 Recombinant modified fibroblast growth factors and therapeutic uses thereof Inactive 28-Mar-2023 A61K38/1825
To view Trefoil Therapeutics’s complete patent history, request access »

Trefoil Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Trefoil Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Solasta Ventures Venture Capital Minority
Access Biotechnology Corporate Venture Capital Minority
Bios Partners Venture Capital Minority
FemHealth Ventures Venture Capital Minority
AJU IB Investment Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Trefoil Therapeutics FAQs

  • When was Trefoil Therapeutics founded?

    Trefoil Therapeutics was founded in 2013.

  • Where is Trefoil Therapeutics headquartered?

    Trefoil Therapeutics is headquartered in San Diego, CA.

  • What is the size of Trefoil Therapeutics?

    Trefoil Therapeutics has 10 total employees.

  • What industry is Trefoil Therapeutics in?

    Trefoil Therapeutics’s primary industry is Drug Discovery.

  • Is Trefoil Therapeutics a private or public company?

    Trefoil Therapeutics is a Private company.

  • What is the current valuation of Trefoil Therapeutics?

    The current valuation of Trefoil Therapeutics is .

  • What is Trefoil Therapeutics’s current revenue?

    The current revenue for Trefoil Therapeutics is .

  • How much funding has Trefoil Therapeutics raised over time?

    Trefoil Therapeutics has raised $49.7M.

  • Who are Trefoil Therapeutics’s investors?

    Solasta Ventures, Access Biotechnology, Bios Partners, FemHealth Ventures, and AJU IB Investment are 5 of 12 investors who have invested in Trefoil Therapeutics.

  • Who are Trefoil Therapeutics’s competitors?

    Casma Therapeutics, Alentis Therapeutics, Cognition Therapeutics, Inovio Pharmaceuticals, and Immusoft are some of the 92 competitors of Trefoil Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process